NateraNTRA
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 4,434
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
284% more first-time investments, than exits
New positions opened: 142 | Existing positions closed: 37
30% more capital invested
Capital invested by funds: $15.3B [Q3] → $19.8B (+$4.52B) [Q4]
21% more funds holding in top 10
Funds holding in top 10: 24 [Q3] → 29 (+5) [Q4]
20% more funds holding
Funds holding: 488 [Q3] → 584 (+96) [Q4]
4.53% more ownership
Funds ownership: 97.2% [Q3] → 101.72% (+4.53%) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 205
17% less call options, than puts
Call options by funds: $136M | Put options by funds: $163M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Piper Sandler David Westenberg 52% 1-year accuracy 24 / 46 met price target | 41%upside $210 | Overweight Maintained | 15 May 2025 |
UBS Elizabeth Garcia 33% 1-year accuracy 1 / 3 met price target | 46%upside $218 | Buy Maintained | 9 May 2025 |
Barclays Luke Sergott 35% 1-year accuracy 22 / 63 met price target | 27%upside $190 | Overweight Maintained | 9 May 2025 |
RBC Capital Conor McNamara 15% 1-year accuracy 6 / 41 met price target | 68%upside $251 | Outperform Initiated | 13 Mar 2025 |
Morgan Stanley Tejas Savant 30% 1-year accuracy 6 / 20 met price target | 24%upside $185 | Overweight Maintained | 5 Mar 2025 |
Financial journalist opinion
Based on 13 articles about NTRA published over the past 30 days









